Maurits H. T. de Ruiter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Maurits H. T. de Ruiter has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Jan de Lange
Department of Oral and Maxillofacial Surgery of the Amsterdam UMC and Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam, Amsterdam, The Netherlands
6 shared publications- Dan M. J. Milstein
Department of Oral and Maxillofacial Surgery, Academic Medical Center, Amsterdam, the Netherlands
2 shared publications - David S. P. Heidsieck
Department of Oral & Maxillofacial Surgery, Academic Medical Centre, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands
2 shared publications J. de Lange
Department of Oral and Maxillofacial Surgery of the Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands
2 shared publications- Linda Berendina Benoist
Department of Otorhinolaryngology Head and Neck Surgery, OLVG West, Jan Tooropstraat 164 1061 AE, Amsterdam, The Netherlands.
2 shared publications Nico de Vries
Department of Otorhinolaryngology Head and Neck Surgery, OLVG West, Jan Tooropstraat 164 1061 AE, Amsterdam, The Netherlands
2 shared publications
Latest Publications
- 2 February 2026
- Published by Nederlands Tijdschrift Voor Tandheelkunde (NTVT) in Nederlands Tijdschrift Voor Tandheelkunde
- Vol. 133 (02) , 96-102
De parodontale gezondheid bij patiënten met obstructieve slaapapneu
Obstructive sleep apnoea is a sleep-related breathing disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during the sleep. The severity of obstructive sleep apnoea is determined by the apnoea-hypopnea index, which represents the number of apnoea s and hypopnea s per hour of sleep. A systematic literature review on the association between obstructive sleep apnoea and the periodontal condition was conducted in the PubMed and Dentistry and Oral Sciences databases. Independent selection and assessment of methodological quality were performed by 2 researchers, followed by a descriptive comparison of the results. From 236 search results, with a total of 462 participants aged 18 to 77, four cross-sectional studies met the inclusion criteria. A significant decrease in clinical attachment level and increase in bleeding tendency was observed in participants with an apnoea-hypopnoea index ? 5. Patients with obstructive sleep apnoea exhibit impaired periodontal health, particularly with regard to clinical attachment level and bleeding tendency. There appears to be a possible association, which may be influenced by shared risk factors.
- 2 February 2026
- Published by Nederlands Tijdschrift Voor Tandheelkunde (NTVT) in Nederlands Tijdschrift Voor Tandheelkunde
- Vol. 133 (02) , 96-102
De parodontale gezondheid bij patiënten met obstructieve slaapapneu
Obstructive sleep apnoea is a sleep-related breathing disorder characterized by repeated episodes of partial or complete obstruction of the upper airway during the sleep. The severity of obstructive sleep apnoea is determined by the apnoea-hypopnea index, which represents the number of apnoea s and hypopnea s per hour of sleep. A systematic literature review on the association between obstructive sleep apnoea and the periodontal condition was conducted in the PubMed and Dentistry and Oral Sciences databases. Independent selection and assessment of methodological quality were performed by 2 researchers, followed by a descriptive comparison of the results. From 236 search results, with a total of 462 participants aged 18 to 77, four cross-sectional studies met the inclusion criteria. A significant decrease in clinical attachment level and increase in bleeding tendency was observed in participants with an apnoea-hypopnoea index ? 5. Patients with obstructive sleep apnoea exhibit impaired periodontal health, particularly with regard to clinical attachment level and bleeding tendency. There appears to be a possible association, which may be influenced by shared risk factors.
- Open Access
- 23 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7494
Patient-Reported Outcome Measures After Botulinum Toxin for Temporomandibular-Related Myalgia: A Prospective Study
Introduction: Botulinum toxin-A (BTX-A) injections are regularly used to treat temporomandibular disorders (TMD). However, consensus regarding the long-term efficacy of BTX-A for TMD-related myalgia remains lacking. This pragmatic, practice-based clinical study aimed to evaluate the Patient-Reported Outcome Measures of pain, health status, quality of life, and function after BTX-A injections in patients with TMD-related myalgia. Methods: This prospective cohort study included 35 patients with TMD-related myalgia who received BTX-A injections in the masseter and temporalis muscles. The Visual Analogue Scale for pain, the EQ-5D-3L for health status, the Oral Health Impact Profile-14 for oral health-related quality of life, the Mandibular Function Impairment Questionnaire for function and the maximum interincisal opening were assessed before treatment and at one, three and six months follow-up. Results: Patients reported a statistically significant and clinically relevant reduction in pain (p < 0.001), improvement of health status (p ≤ 0.003), and oral health-related quality of life (p < 0.001) at one-month follow-up, which remained present at three and six months post-treatment. Self-reported mandibular function and active and passive mouth opening showed no significant change over all time points. Conclusions: In this pragmatic cohort, BTX-A injections in the masseter and temporalis muscles seem to improve pain and oral health-related quality of life in patients with TMD-related myalgia within one month and show effects lasting up to six months, while mandibular function did not improve.
- 23 October 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (21) , 7494
Open AccessPatient-Reported Outcome Measures After Botulinum Toxin for Temporomandibular-Related Myalgia: A Prospective Study
Introduction: Botulinum toxin-A (BTX-A) injections are regularly used to treat temporomandibular disorders (TMD). However, consensus regarding the long-term efficacy of BTX-A for TMD-related myalgia remains lacking. This pragmatic, practice-based clinical study aimed to evaluate the Patient-Reported Outcome Measures of pain, health status, quality of life, and function after BTX-A injections in patients with TMD-related myalgia. Methods: This prospective cohort study included 35 patients with TMD-related myalgia who received BTX-A injections in the masseter and temporalis muscles. The Visual Analogue Scale for pain, the EQ-5D-3L for health status, the Oral Health Impact Profile-14 for oral health-related quality of life, the Mandibular Function Impairment Questionnaire for function and the maximum interincisal opening were assessed before treatment and at one, three and six months follow-up. Results: Patients reported a statistically significant and clinically relevant reduction in pain (p < 0.001), improvement of health status (p ≤ 0.003), and oral health-related quality of life (p < 0.001) at one-month follow-up, which remained present at three and six months post-treatment. Self-reported mandibular function and active and passive mouth opening showed no significant change over all time points. Conclusions: In this pragmatic cohort, BTX-A injections in the masseter and temporalis muscles seem to improve pain and oral health-related quality of life in patients with TMD-related myalgia within one month and show effects lasting up to six months, while mandibular function did not improve.
- Open Access
- 31 July 2020
- Published by Taylor & Francis in Cranio®
- Vol. 41 (1) , 16-21
Facial esthetics and subjective impairment assessed after maxillomandibular advancement surgery for patients with obstructive sleep apnea
To assess facial esthetics and quality of life (QoL) as measure of success or failure after maxillomandibular advancement (MMA) surgery for obstructive sleep apnea (OSA). Visual analog scales (VAS)...
- 31 July 2020
- Published by Taylor & Francis in Cranio®
- Vol. 41 (1) , 16-21
Open AccessFacial esthetics and subjective impairment assessed after maxillomandibular advancement surgery for patients with obstructive sleep apnea
To assess facial esthetics and quality of life (QoL) as measure of success or failure after maxillomandibular advancement (MMA) surgery for obstructive sleep apnea (OSA). Visual analog scales (VAS)...
- Open Access
- 11 March 2020
- Published by Springer Nature in Sleep and Breathing
- Vol. 24 (3) , 1229-1236
A stepwise titration protocol for oral appliance therapy in positional obstructive sleep apnea patients: proof of concept
Purpose: In patients with positional obstructive sleep apnea (POSA), oral appliance therapy (OAT) is among the first-line treatments. The aim of this study was to evaluate the effects of a new standardized stepwise titration protocol for OAT in a group of patients with POSA. Methods: This was an observational intervention trial. Patients who were previously randomized to the OAT intervention arm of a comparison study comprised the subjects for this study. These patients, who had mild to moderate POSA, were assessed after 3 and 12 months for treatment efficacy, objective adherence by temperature microsensor, and side effects. The titration of OAT was performed using a standardized stepwise titration protocol including advancement levels of 60%, 75%, and 90% of the maximum mandibular protrusion. The optimal advancement level per individual was based on a weighted compromise between efficacy and side effects. Results: In total, 36 patients were included and all completed the titration protocol after 3 months. At baseline, the OAT was set at 60% of the maximal mandibular protrusion position. At a 3-month evaluation, the advancement remained at 60% in 16 patients (44%) and reached 75% advancement in 20 patients (56%). Mean apnea-hypopnea index decreased from 12.9 events per hour (9.1–16.7) to 6.9 (3.7–10.3) (P < 0.001), and median objective adherence was 97.4 (61.4–100.00) after 3 months. The 12-month analysis showed consistent results and good OAT tolerance. Six patients (16.7%) terminated OAT and one patient (2.8%) was lost to follow-up. Conclusions: This standardized stepwise titration protocol for OAT showed good efficacy, good OAT tolerance, and good objective adherence in patients with mild to moderate POSA. Therefore, the protocol is recommended in research projects to improve standardization of methods between studies and in clinical practice for its practical feasibility.
- 11 March 2020
- Published by Springer Nature in Sleep and Breathing
- Vol. 24 (3) , 1229-1236
Open AccessA stepwise titration protocol for oral appliance therapy in positional obstructive sleep apnea patients: proof of concept
Purpose: In patients with positional obstructive sleep apnea (POSA), oral appliance therapy (OAT) is among the first-line treatments. The aim of this study was to evaluate the effects of a new standardized stepwise titration protocol for OAT in a group of patients with POSA. Methods: This was an observational intervention trial. Patients who were previously randomized to the OAT intervention arm of a comparison study comprised the subjects for this study. These patients, who had mild to moderate POSA, were assessed after 3 and 12 months for treatment efficacy, objective adherence by temperature microsensor, and side effects. The titration of OAT was performed using a standardized stepwise titration protocol including advancement levels of 60%, 75%, and 90% of the maximum mandibular protrusion. The optimal advancement level per individual was based on a weighted compromise between efficacy and side effects. Results: In total, 36 patients were included and all completed the titration protocol after 3 months. At baseline, the OAT was set at 60% of the maximal mandibular protrusion position. At a 3-month evaluation, the advancement remained at 60% in 16 patients (44%) and reached 75% advancement in 20 patients (56%). Mean apnea-hypopnea index decreased from 12.9 events per hour (9.1–16.7) to 6.9 (3.7–10.3) (P < 0.001), and median objective adherence was 97.4 (61.4–100.00) after 3 months. The 12-month analysis showed consistent results and good OAT tolerance. Six patients (16.7%) terminated OAT and one patient (2.8%) was lost to follow-up. Conclusions: This standardized stepwise titration protocol for OAT showed good efficacy, good OAT tolerance, and good objective adherence in patients with mild to moderate POSA. Therefore, the protocol is recommended in research projects to improve standardization of methods between studies and in clinical practice for its practical feasibility.
- 1 February 2018
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 46 (2) , 288-292
Biomechanical effects of a mandibular advancement device on the temporomandibular joint
- 1 February 2018
- Published by Elsevier in Journal of Cranio-Maxillofacial Surgery
- Vol. 46 (2) , 288-292
Biomechanical effects of a mandibular advancement device on the temporomandibular joint
- 1 January 2018
- Vol. 76 (1) , 40-42
Fulminant presentation of oral mucosal leishmaniasis as severe stomatitis and periodontitis
This case report shows an atypical presentation of mucosal leishmaniasis infantum in the oral cavity resulting in severe stomatitis and periodontitis. The patient was immunocompromised because of rheumatoid arthritis for which he used prednisone and methotrexate. He was treated with intravenous liposomal amphotericin B and recovered within four weeks.
- 1 January 2018
- Vol. 76 (1) , 40-42
Fulminant presentation of oral mucosal leishmaniasis as severe stomatitis and periodontitis
This case report shows an atypical presentation of mucosal leishmaniasis infantum in the oral cavity resulting in severe stomatitis and periodontitis. The patient was immunocompromised because of rheumatoid arthritis for which he used prednisone and methotrexate. He was treated with intravenous liposomal amphotericin B and recovered within four weeks.
- 1 November 2017
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 46 (11) , 1357-1362
Assessment of obstructive sleep apnoea treatment success or failure after maxillomandibular advancement
- 1 November 2017
- Published by Elsevier in International Journal of Oral and Maxillofacial Surgery
- Vol. 46 (11) , 1357-1362
Assessment of obstructive sleep apnoea treatment success or failure after maxillomandibular advancement
- Open Access
- 15 September 2017
- Published by Springer Nature in Sleep and Breathing
- Vol. 22 (2) , 441-450
Durability of treatment effects of the Sleep Position Trainer versus oral appliance therapy in positional OSA: 12-month follow-up of a randomized controlled trial
Purpose The Sleep Position Trainer (SPT) is a new option for treating patients with positional obstructive sleep apnea (POSA). This study investigated long-term efficacy, adherence, and quality of life during use of the SPT device compared with oral appliance therapy (OAT) in patients with POSA. Methods This prospective, multicenter trial randomized patients with mild to moderate POSA (apnea-hypopnea index [AHI] 5–30/h) to SPT or OAT. Polysomnography was performed at baseline and after 3 and 12 months’ follow-up. The primary endpoint was OSA severity; adherence, quality of life, and adverse events were also assessed. Results Ninety-nine patients were randomized and 58 completed the study (29 in each group). Median AHI in the SPT group decreased from 13.2/h at baseline to 7.1/h after 12 months (P < 0.001); corresponding values in the OAT group were 13.4/h and 5.0/h (P < 0.001), with no significant between-group difference (P = 1.000). Improvements throughout the study were maintained at 12 months. Long-term median adherence was also similar in the two treatment groups; the proportion of patients who used their device for ≥ 4 h for 5 days in a week was 100% in the SPT group and 97.0% in the OAT group (P = 0.598). Conclusions The efficacy of SPT therapy was maintained over 12 months and was comparable to that of OAT in patients with mild to moderate POSA. Adherence was relatively high, and similar in the two groups. Trial registration: www.clinicaltrials.gov (NCT02045576).
- 15 September 2017
- Published by Springer Nature in Sleep and Breathing
- Vol. 22 (2) , 441-450
Open AccessDurability of treatment effects of the Sleep Position Trainer versus oral appliance therapy in positional OSA: 12-month follow-up of a randomized controlled trial
Purpose The Sleep Position Trainer (SPT) is a new option for treating patients with positional obstructive sleep apnea (POSA). This study investigated long-term efficacy, adherence, and quality of life during use of the SPT device compared with oral appliance therapy (OAT) in patients with POSA. Methods This prospective, multicenter trial randomized patients with mild to moderate POSA (apnea-hypopnea index [AHI] 5–30/h) to SPT or OAT. Polysomnography was performed at baseline and after 3 and 12 months’ follow-up. The primary endpoint was OSA severity; adherence, quality of life, and adverse events were also assessed. Results Ninety-nine patients were randomized and 58 completed the study (29 in each group). Median AHI in the SPT group decreased from 13.2/h at baseline to 7.1/h after 12 months (P < 0.001); corresponding values in the OAT group were 13.4/h and 5.0/h (P < 0.001), with no significant between-group difference (P = 1.000). Improvements throughout the study were maintained at 12 months. Long-term median adherence was also similar in the two treatment groups; the proportion of patients who used their device for ≥ 4 h for 5 days in a week was 100% in the SPT group and 97.0% in the OAT group (P = 0.598). Conclusions The efficacy of SPT therapy was maintained over 12 months and was comparable to that of OAT in patients with mild to moderate POSA. Adherence was relatively high, and similar in the two groups. Trial registration: www.clinicaltrials.gov (NCT02045576).
- 1 June 2017
- Published by Elsevier in Sleep Medicine
- Vol. 34, 109-117
A randomized, controlled trial of positional therapy versus oral appliance therapy for position-dependent sleep apnea
- 1 June 2017
- Published by Elsevier in Sleep Medicine
- Vol. 34, 109-117
A randomized, controlled trial of positional therapy versus oral appliance therapy for position-dependent sleep apnea
- 1 May 2016
- Published by Elsevier in Sleep Medicine
- Vol. 21, 19-27
Three-dimensional imaging of the upper airway anatomy in obstructive sleep apnea: a systematic review
- 1 May 2016
- Published by Elsevier in Sleep Medicine
- Vol. 21, 19-27
Three-dimensional imaging of the upper airway anatomy in obstructive sleep apnea: a systematic review